Aurinia Pharmaceuticals Inc. has grown revenue 25% a year over three years and 40% a year over five. Revenue growth, 3-year annual rate: +25% (Biotechnology median +17%). Revenue growth, 5-year rate: +40%, growth has slowed since the five-year average. Years of annual history on file: 8, FY2018 to FY2025, as filed.

AUPHAurinia Pharmaceuticals Inc.

Healthcare

$16.65+28% 1Y

$16.65

$11.0552 weeks$18.62

Is it growing?

Excellent

Growing: revenue growing +20% year on year, earnings up +433% year on year, and operating margin widening (+28.6 points).

3 good

Revenue trend+20% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +40% a year.

Earnings trend+433% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing faster than revenue, so margins or the share count are helping.

Margin direction+28.6 points operating

Trailing-twelve-month operating margin, 48.1% now against 19.6% a year earlier.

All from SEC EDGAR, as of Jun 30, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is AUPH growing?

Aurinia Pharmaceuticals Inc. has grown revenue 25% a year over three years and 40% a year over five.

+25%

Revenue growth, 3-year annual rate · Biotechnology median +17% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +40%
Revenue growth, 5-year rate · +25% over three · growth has slowed since the five-year average
Years of annual history on file: 8
Years of annual history on file · FY2018 to FY2025, as filed

Details›